Related Experiment Video
Updated: May 7, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 19, 2013
A new therapeutic target for leukemia comes to the surface
David S Ritchie1, Mark J Smyth
1Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, 3002, Victoria, Australia. david.ritchie@petermac.org
Abstract:
Expression of the cell-surface protein CD47 allows some normal cells to avoid phagocytosis by macrophages. In this issue, Jaiswal et al. (2009) and Majeti et al. (2009) show that elevated CD47 expression by leukemic stem cells inhibits macrophage activity and is an indicator of poor prognosis for patients with acute myeloid leukemia.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Tumor Immunotherapy

